Close this search box.

RNA Insights

Thomas Foster Joins RNA Advisors as Managing Principal

RNA Advisors, LLC, a leading valuation and strategic advisory firm focused exclusively on life sciences and healthcare technology, announced today that Thomas Foster has joined the firm as Managing Principal. Mr. Foster is a commercial expert and strategist who focuses on turning science into profitable revenue streams and corporate value. His work provides independent and objective advisory services that include pricing & market access, opportunity assessment, new product planning, valuation, transaction support and company strategy. Mr. Foster has advised over 300 life sciences, healthcare and technology and has worked as part of teams that have priced 7 of the 10 best-selling life sciences products of all time. Based in the Washington DC area, Mr. Foster will work with RNA’s other senior officers to deliver a comprehensive range of strategic advisory, market assessment, valuations, and transaction support services.

Mr. Foster joins RNA Advisors with over 30 years of experience evaluating value and risk for clients in life sciences as well as on Wall Street. His work has pioneered innovative valuation techniques for assets without existing market analogs and he is an expert in decision-support frameworks that translate uncertainty into quantifiable risk. Most recently, he was Managing Partner at Foster Rosenblatt, a leading global advisory & firm focusing exclusively on the healthcare and life sciences industries. Prior, he was VP of Consulting at IQVIA. He was also SVP of Strategy at Cambridge Pharma Consultancy, and Practice Leader at PAREXEL. In 2018, Thomas was recognized by the Pharmaceutical Management Science Association (PMSA) with the prestigious Lifetime Achievement Award.

“Thomas brings invaluable skills and experience to the RNA team as a respected innovator in the valuation field. We are particularly excited to welcome him at RNA Advisors,” said Sam Renwick, Founding Principal and CEO. “Thomas has extensive experience developing pricing methodologies and providing actionable, strategic insights to life sciences, healthcare, and technology clients. His depth of knowledge and professional exposure combined with his passion for excellence in client service will be a powerful platform for success for RNA as we move towards the start of our second decade of growth.”

Thomas Foster notes, “I am truly honored to be joining the well-respected team at RNA Advisors. We have a combination of talent and innovative methods that makes us a great fit for our clients as we navigate the rising complexities of value assessment, value optimization and value creation. I am very excited to start this journey with RNA as we support our clients by providing an unprecedented level of insight into their opportunities, risks and valuations.”

About RNA Advisors

RNA Advisors is a leading financial advisory and valuation consulting firm focused exclusively in the life sciences and healthcare sectors. Since the firm’s founding in 2015, RNA Advisors has provided over 300 clients across life sciences and healthcare verticals with strategic decision analysis, valuation, and transactional support for thousands of transactions worth over $282 billion in asset and transaction value. RNA assists life sciences and healthcare technology companies and investors by providing research, analysis and consulting support for highly strategic transactions, acquisitions, and commercial partnerships. RNA Advisors’ clients include private venture-backed and public companies in biotech, biopharmaceuticals, digital health, medical devices, healthcare services and technology, as well as royalty stream investors, potential joint venture partners, M&A transaction counterparties, financiers and licensors/licensees. RNA’s deeply experienced team includes 20+ consultants and analysts delivering high-level to deep-dive market assessments, market research, comparative valuation analyses, and financial modeling and forecasts which support decision making around corporate growth strategies. RNA Advisors also delivers end-to-end transaction support in the form of fairness opinions, intellectual property valuations, asset and enterprise valuations, drug royalty forecasts, derivative security valuations, pro forma capitalization table modeling, and gift/estate tax valuations for investors. Learn more about RNA Advisor client success stories at

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.